Background. Functional impairment over time is a necessary condition for the diagnosis of dementia. Increasingly, it is recognized that rates of decline may not follow a linear progression. This variability may indicate that dementia in Alzheimer's disease represents disease rather than inevitable aging. In order to investigate decline in function in dementia, we developed a model of the rate of decline in functions in Alzheimer's disease and in other dementias in comparison with normal aging.
T HE diagnosis of dementia requires the presence of acquired functional impairment shown oVfr time (1) . How to best operationalize functional impairment is not yet clear, in part because of marked heterogeneity in premorbid functional capability, and in part because of the lack of a clear consensus about what represents "normal" losses among very elderly adults, in whom dementia is most common (2) . While better methods of assessing functional impairment in dementia are being developed (3) (4) (5) (6) (7) (8) , the related matter of how to gauge the rate of decline has received less attention (9) (10) (11) (12) (13) (14) (15) . Brooks et al. (12) noted that the usual (often implicit) assumption of a linear model of decline fails to adequately capture the variable rates of decline seen in different stages of Alzheimer's disease. They proposed, instead, a trilinear model of decline and presented several illustrative cases as well as a hypothetical cohort study in support of their approach. The trilinear model was itself subsequently criticized for the assumption of a stable interval prior to diagnosis (16) . Recent position emission tomography (PET) data demonstrating subtle deficits long before any cognitive impairment is demonstrated suggest, however, thatthe decline may be present earlier than has usually been assumed (17) .
The question of the rate of decline goes to the heart of the persistent controversy over whether dementia in Alzheimer's disease represents disease or inevitable aging (14, (18) (19) (20) (21) . We therefore calculated rates of decline using the Canadian Study of Health and Aging database. The rates of decline were compared in those who experience cognitively normal aging, those with cognitive impairment but no dementia (CIND), and those with mild, moderate, and severe levels of Alzheimer's disease, vascular dementia, and other dementias.
METHODS
Population database.-The Canadian Study of Health and Aging (CSHA) database constitutes a national, crosssectional, representative sample of Canadians aged 65 and older. The study methods and clinical examinations are described elsewhere (22, 23) . Of the 10,263 elderly Canadians screened for cognitive impairment, those with a score of 77 or less on the Modified Mini-Mental State (3MS) Exam (24) and a sample of those who screened negative received an extensive clinical assessment (N = 2,914). This resulted in the diagnosis of 921 people with no cognitive impairment, 861 with some cognitive impairment but no dementia, and 1,132 people with dementia.
Identifying redundancies in the variables allowed us to reduce the original set of 400 clinical symptoms and signs to 26 (25~26). We examined the following diagnostic groups: no cognitive impairment (NCI); cognitive impairment no dementia (CIND); probable Alzheimer's disease (AD); four subtypes of possible AD which comprise possi-M66
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Taking into account that the standard deviation of p is sufficiently smaller than the standard deviation of b, the stanDynamic model of impairment.-The suggested model is based on the assumption that beginning from an age to, the rate of the emergence of a new sign dnddt is proportional to the number of retained normal signs no-nl, where no is the total number of items:
Estimation of the beginning of functional decline.-Let us first estimate the beginning of functional decline, to, (the onset) as the average value across all subjects independent of the diagnosis. Applying formula 3 to all N = 2,914 subjects, we can estimate the parameters of the linear time regression of the logeI-pI):
where t is age in years and p is a coefficient with the dimension lIyear. Let P = ndn« be the proportion of the newly emerged items from the total number of items (i.e., P is the probability of an occurrence for a sign). We can rewrite Equation 1 in the form:
(4)
The solution of Equation 2 is as follows:
where t is the patient's age, and to is the age at the beginning of functional decline. For every patient, the age t may be obtained from the database, and the impairment index p may be calculated for the given items. Two constants of the model remain unknown: p -rate of the decline and to -the beginning of the decline in functions. These parameters were estimated using linear regression techniques.
Least square estimates of the regression coefficients are b = .078181, and p = .004686; standard deviations are <J'b = .062145 and <J'p = .000755 for b and p, respectively. The correlation coefficient, r, between -logeI-p) and t, equals .1143. Taking into account the large number of observations, the obtained value of r corresponds to the significance levelp < .000001, and it ensures the model 1-3.
The parameter to may be found according to Equation 4 as a ratio: ble AD with atypical presentation, possible AD with a vascular component, possible AD with Parkinsonism, and possible AD with comorbid illness; and vascular dementia, and Parkinson's dementia. To explore greater characterization within the disease categories, we analyzed as separate categories the three levels of severity (mild, moderate, and severe) for probable AD and vascular dementia, based upon ICD-I0 criteria (27) .
RESULTS
Analysis.-We proceeded to define an impairment index from the 26 symptoms and signs. Let us consider the set of N binary symptoms and signs from the CSHA database. Let Pi be a proportion of symptoms and signs (items) present for the ith subject at the time of examination. Thus, Pi estimates the probability of the occurrence of an item for the ith subject. Let us consider the average of this probability for the diagnostic group, 1Tj ='Lpi1M, i=I, ...,M, where M is the number of subjects within the jth diagnostic group. Accordingly, 1Tj may be defined as an impairment index for the disease, while Pi is the impairment index for the ith patient. The standard deviation, <J'j and median, Jlj, may be calculated by taking into account the empirical distribution of Pi for jth group. Linear regression techniques were applied to estimate the parameters of the linear model. The chi-square test was used to compare the empirical distribution with the hypothetical distribution.
By modeling decline over time, we can examine the rate of decline and estimate, approximately, the onset of the decline. In particular, we investigated the distribution of cognitive impairment across the specific disease categories. This, in tum, permits us to venture further claims about the rate of decline and about age at onset. Hence, this method allows us to make inferences across age and progression. Table 1 , the impairment index, standard deviation, standard error, and median are presented for all diagnostic groups. As can be seen, the values of the index vary sufficiently between the normal (.0962) and impaired groups, and increase noticeably with disease severity (e.g., from .3418 for mild to .5777 for severe vascular dementia). In addition, it is apparent that the values of the impairment index (which is the mean averaged across all subjects in the group) are close to the medians. Figure 1 demonstrates that the unimpaired group has an exponential distribution for the parameter p. It was also found that for those with CIND, the distribution of the rate parameter also remains exponential. In contrast, for those with dementia the rate parameter, p, does not show an exponential distribution. In Figures 2 and 3 , the distributions for mild and severe Alzheimer's disease, respectively, are presented: the distribution of the logarithm of the rate is normal, which ensured the log-normal distribution of the decline rate. In Figure 4 , the distribution for severe vascular dementia is shown, which is also log-normal. Decline rate. l /year tic categories. The rate is minimal for those aging normally, but increases as the dementia severity progresses. Two distinct probability distributions for the rate of decline characterize the population: cognitively normal elderly show an exponential distribution, whereas those with dementia have a log-normal distribution .
Impairment index for different diagnostic groups.-In

(6) p = -(log[l-pD/(t -to).
Calculation of the decline rate, p for different diagnostic groups.-Since to was estimated, and substituting p across all the subjects in Equation 6, we can obtain values for the decline rate p. In Table 2 , the values of the mean and standard deviation are presented. The mean values increase with the severity of the diagnosis . In addition, there is an increase in the difference in values between means and standard deviations from the group aging normally. Comparing the mean value with the standard deviation, they are found to be equal for the normal aging group, relatively close for the CIND group, but increase for successive stages of mild, moderate, and severe probable Alzheimer's disease. This suggests that the type of distribution for the parameter p is changing as the severity of dementia progresses. Moreover, a similar pattern holds for increasing severity of vascular dementia. Log (decline rate ) Figure 4 . Distribution of the logarithm of the decline rate for severe vascular dementia. The histogram represents the rate parameter, and the curve is a log-normal distribution with the parameters, mean (log p) = -4.33360, SD = .4787.
We are aware of three important limitations to this study. First, data are cross-sectional, not longitudinal, so assessments of decline are biased toward survivors within each stage. Although patients can have more or less rapid courses, differential survival patterns have not been described to any important extent in AD; decline toward an advanced stage, followed by death, is the most common pattern (9-13). Nevertheless, our claim about rates of impairment requires confirmation in a cohort study, the data collection for which is now complete for the second phase of the CSHA. Second, in an effort to describe a simple model at the outset, we have limited our analyses to a reduced set of 26 clinical symptoms and signs that proved sufficient in earlier analyses to distinguish between nondementia and dementia, and between types of dementia (26) . These 26 signs and symptoms are not exhaustive, however. Third, we determined the onset parameter for the entire population. If we attempted to estimate this for each diagnostic group, our statistical interpretations would be limited by the small number of cases in several categories. By estimating the same onset for the entire population of 2,914 cases we can employ all available data. We use this onset parameter to substitute in Equation 6 in order to calculate the rate for each subject and thereby get the distribution of the rate parameter, p, for the different groups, even though we recognize variability in the onset and rate of decline within cognitive domains of even a single diagnosis (28) . This assumption does not influence the difference between distributions derived for the different diagnostic groups. Indeed, the rate was derived separately for each diagnostic group, and was found to be significantly different for the majority of diagnostic groups.
The model of the decline.-For the initial stage, we considered the simplest model for developing a deficit in time.
To build a dynamic model we relate the rate of the emergence of a sign (the presence of a sign indicates an emerging impairment of the system) with the current state of the system (expressed by the number or proportion of signs). Such a relationship may be rather complex, paralleling the complexity of the governing processes. Since these processes remain unknown , it makes sense to use a simplified model with a small number of the interpretable parameters. Therefore, as a first approximation, we suggested a linear equation (1) . Our purpose was to estimate the rate parameter of this equation (p) and to compare this parameter for different pathologies and for usual (unimpaired) aging. According to this simplest model, the rate parameter was considered as a constant. The values of this parameter differ among the various diagnostic groups . They also increase with the severity of the disease, thereby providing construct validity. Because our model represents an ideal version of the actual complex process of functional decline, the rate parameter is an averaged value across the considered symptoms and signs and across the subjects within the diagnostic groups.
Dependence between different symptoms and signs is an essential characteristic of human systems (26) . The question remains how this dependence may influence the results of our modeling, as statistical linkages between the symptoms and signs exist. As with any model, our model is an ideal of a real situation. By suggesting the linear model, we neglected the effects of the relationships between some signs by assuming that those effects play a less important role than the effects of other signs that are independent. In order to test the validity of the assumption of independence, we analyzed the statistical distributions of the rate parameter, p. Since both distributions (exponential for usual aging and log-normal for dementia) are the distributions produced by the action of multiple independent factors, we can conclude that the assumption of independence does not contradict experimental data. In other words, the influence of separate symptoms and signs significantly exceeds the effects of interaction and dependency, not denying the very fact of these dependencies for some symptoms and signs. This also corresponds with evidence for weakening of dependency between the symptoms and signs (coordination of signs) in dementia groups (26) .
The impairment index.-The values of the impairment index differ among the various diagnostic groups, supporting the construct validity of this measure of impairment. Moreover, the value of this index increases with the severity of the disease. The close values of the mean and median further suggest that the index we describe represents a valid measure of impairment.
The rate of decline.-The nature of the distribution of the rate of decline of functions (i.e., impairment index) reflects essential differences in the process of impairment between those with dementia and the cognitively unimpaired. The exponential distribution (unimpaired subjects) may be interpreted as indicating a random process with rare emergence of symptoms and signs, with few cases with a rate of decline greater than .008 per year (Figure 1 ). In fact, the exponential function is often viewed as a distribution of rare events. By contrast, in severe dementia the distribution is log-normal and most subjects have rate of decline values much greater than .008. It is clear, therefore, that there are two distinct distributions, different in both shape and rate of aging. These differences indicate three important characteristics : the unimpaired have a much smaller mean rate than the impaired; the severely impaired have a greater rate than the mild or moderately impaired; and , of note , the distribution of the rate parameter among the individuals is also different for the nor-mal and the cognitively impaired. This implies, as expected, that there is a different process underlying the decline in functions in those with and without cognitive impairment.
We believe that the model of impairment suggested here (Equations 1-3) is a useful approximation of the process of decline in function in cognitive impairment and dementia. For the purposes of this analysis, our impairment index is restricted to the 26 symptoms and signs identified in Appendix 1. It does not represent a comprehensive functional impairment (disability) measure. At this stage, we have limited our model to a rate of decline as a constant in time (i.e., this rate parameter does not change with age), in order to demonstrate that different diagnostic groups may be distinguished by this parameter. Future studies will need to pay more attention to the structure of the rate, both in respect to different diagnostic groups and in respect to possible time dependence of this parameter. A particularly important consideration is that while the goal of several experimental drugs is to slow the rate of decline in Alzheimer's disease, the definition of success is critically dependent on the rate of decline model. Refinements gained by models such as that proposed here are likely to be increasingly important as we attempt to understand such novel conditions as treated Alzheimer's disease.
